Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) deadline 2026
The current listed application deadline is June 2, 2026. Use this page to verify timing fast, then move into the full grant record for planning, comparison, and drafting.
Application Countdown
Use this page as the fast check for timing, then jump into the full grant record for filters, drafting, and comparison.
Quick facts
- Opportunity number
- RFA-TR-25-002
- Last updated
- December 6, 2024
- Expected awards
- Not listed
Deadline summary
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare dis...
Key dates
Before you apply
Eligibility snapshot
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
